Ayşe Esra Manguoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayşe Esra Manguoğlu has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Güven Lüleci
Department of Medical Biology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
4 shared publicationsAkif Yeşilipek
1 shared publicationAkin Sevinç
Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey
1 shared publicationAli Esat Karakaya
1 shared publication- Alphan Kupesiz
Division of Hematology, Department of Paediatrics, Faculty of Medicine, Akdeniz University, 07070 Antalya, Turkey
1 shared publication Alphan Küpesiz
1 shared publication
Latest Publications
- 3 May 2024
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 19 (3) , 217-227
From islet transplantation to beta-cell regeneration: an update on beta-cell-based therapeutic approaches in type 1 diabetes
IntroductionType 1 diabetes (T1D) mellitus is an autoimmune disease in which immune cells, predominantly effector T cells, destroy insulin-secreting beta-cells. Beta-cell destruction led to various consequences ranging from retinopathy and nephropathy to neuropathy. Different strategies have been developed to achieve normoglycemia, including exogenous glucose compensation, whole pancreas transplantation, islet transplantation, and beta-cell replacement.Areas coveredThe last two decades of experience have shown that indigenous glucose compensation through beta-cell regeneration and protection is a peerless method for T1D therapy. Tremendous studies have tried to find an unlimited source for beta-cell regeneration, on the one hand, and beta-cell protection against immune attack, on the other hand. Recent advances in stem cell technology, gene editing methods, and immune modulation approaches provide a unique opportunity for both beta-cell regeneration and protection.Expert opinionPluripotent stem cell differentiation into the beta-cell is considered an unlimited source for beta-cell regeneration. Devising engineered pancreas-specific regulatory T cells using Chimeric Antigen Receptor (CAR) technology potentiates an effective immune tolerance induction for beta-cell protection. Beta-cell regeneration using pluripotent stem cells and beta-cell protection using pancreas-specific engineered regulatory T cells promises to develop a curative protocol in T1D.
- 3 May 2024
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 19 (3) , 217-227
From islet transplantation to beta-cell regeneration: an update on beta-cell-based therapeutic approaches in type 1 diabetes
IntroductionType 1 diabetes (T1D) mellitus is an autoimmune disease in which immune cells, predominantly effector T cells, destroy insulin-secreting beta-cells. Beta-cell destruction led to various consequences ranging from retinopathy and nephropathy to neuropathy. Different strategies have been developed to achieve normoglycemia, including exogenous glucose compensation, whole pancreas transplantation, islet transplantation, and beta-cell replacement.Areas coveredThe last two decades of experience have shown that indigenous glucose compensation through beta-cell regeneration and protection is a peerless method for T1D therapy. Tremendous studies have tried to find an unlimited source for beta-cell regeneration, on the one hand, and beta-cell protection against immune attack, on the other hand. Recent advances in stem cell technology, gene editing methods, and immune modulation approaches provide a unique opportunity for both beta-cell regeneration and protection.Expert opinionPluripotent stem cell differentiation into the beta-cell is considered an unlimited source for beta-cell regeneration. Devising engineered pancreas-specific regulatory T cells using Chimeric Antigen Receptor (CAR) technology potentiates an effective immune tolerance induction for beta-cell protection. Beta-cell regeneration using pluripotent stem cells and beta-cell protection using pancreas-specific engineered regulatory T cells promises to develop a curative protocol in T1D.
- Open Access
- 9 April 2024
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 25 (1) , 1-8
Turkish population-based screening for first identified changes of BRCA1 and BRCA2 genes in breast and/or ovarian cancer patients
Introduction: It is known that BRCA1 and BRCA2 genes’ mutation carriers are predisposed to breast and ovarian cancers and other organ cancers such as prostate, colon and cervix. In the previous study performed at X University, all coding exons of both genes were screened by denaturing gradient gel electrophoresis (DGGE). In addition to various nonsense, missense mutations, polymorphisms and intronic region changes, seven novel missense mutations, including H513L, H816P and S1517Y in BRCA1 and S326R, G258P, E2903K and N2742S in BRCA2, had been identified. Methods: To determine whether these unclassified variants are pathogenic, DNA samples of 150 healthy individuals without a known cancer history in the family were screened in this study for these seven novel missense mutations. These DNA samples were recruited from archives of previous polymorphism studies. PCR performed DNA amplifications, and denaturing high-performance liquid chromatography (DHPLC) techniques did mutation screenings. Results: Peak patterns suggestive of a change in DNA fragments were considered for sequencing analyses. Analyses revealed that none of the 150 DNA samples had any change in the seven screened fragments. As a result, it is assumed that these seven mutations might be novel pathogenic mutations described in the Turkish population. Conclusion: In conclusion, these carriers must be informed about the mutation and given appropriate genetic counseling by their physicians. In addition, genetic testing must be offered to high-risk individuals (men/women) in the family so that it would be possible for other family members to have genetic counseling and contribute to disease prevention. On the other hand, these findings would contribute to current literature with novel results and shed light on future research.
- 9 April 2024
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 25 (1) , 1-8
Open AccessTurkish population-based screening for first identified changes of BRCA1 and BRCA2 genes in breast and/or ovarian cancer patients
Introduction: It is known that BRCA1 and BRCA2 genes’ mutation carriers are predisposed to breast and ovarian cancers and other organ cancers such as prostate, colon and cervix. In the previous study performed at X University, all coding exons of both genes were screened by denaturing gradient gel electrophoresis (DGGE). In addition to various nonsense, missense mutations, polymorphisms and intronic region changes, seven novel missense mutations, including H513L, H816P and S1517Y in BRCA1 and S326R, G258P, E2903K and N2742S in BRCA2, had been identified. Methods: To determine whether these unclassified variants are pathogenic, DNA samples of 150 healthy individuals without a known cancer history in the family were screened in this study for these seven novel missense mutations. These DNA samples were recruited from archives of previous polymorphism studies. PCR performed DNA amplifications, and denaturing high-performance liquid chromatography (DHPLC) techniques did mutation screenings. Results: Peak patterns suggestive of a change in DNA fragments were considered for sequencing analyses. Analyses revealed that none of the 150 DNA samples had any change in the seven screened fragments. As a result, it is assumed that these seven mutations might be novel pathogenic mutations described in the Turkish population. Conclusion: In conclusion, these carriers must be informed about the mutation and given appropriate genetic counseling by their physicians. In addition, genetic testing must be offered to high-risk individuals (men/women) in the family so that it would be possible for other family members to have genetic counseling and contribute to disease prevention. On the other hand, these findings would contribute to current literature with novel results and shed light on future research.
- 1 November 2023
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 25 (3-4) , 336-344
Autophagy dysregulation plays a crucial role in regulatory T-cell loss and neuroinflammation in amyotrophic lateral sclerosis (ALS)
Objective: Neuroinflammation is the hallmark of amyotrophic lateral sclerosis (ALS) disease. Regulatory T cells (Tregs) are essential in immune tolerance and neuroinflammation prevention. It has been shown that a significant decrease in Treg and FoxP3 protein expression is observed in ALS patients. The main reason for the FoxP3(+) Treg loss in ALS is unknown. In this study, the role of autophagy dysregulation in FoxP3(+) Tregs in ALS was investigated.Methods: Twenty-three ALS patients and 24 healthy controls were recruited for the study. Mononuclear cells (MNCs) were obtained from peripheral blood, and then Tregs were isolated. Isolated Tregs were stained with FoxP3 and LC3 antibodies and analyzed in flow cytometry to determine autophagy levels in FoxP3(+) Tregs in patients and controls.Results: The mean of FoxP3(+) LC3(+) cells, were 0.47 and 0.45 in patients and controls, respectively. The mean of FoxP3(+) LC3- cells was 0.15 in patients and 0.20 in controls, p = 0.030 (p < 0.05). There is no significant correlation between ALSFRS-R decay rate and autophagy level in patients. Also, there is no significant difference between autophagy levels in FoxP3(+) Tregs in patients with rapidly progressing ALS and slow-progressing ALS.Conclusion: Excessive autophagy levels in FoxP3(+) Tregs in ALS patients can potentially be an explanation for an increased cell death and result in worsened neuroinflammation and disease onset. However, the disease progress is not attributable to autophagy levels in FoxP3(+) Tregs.
- 1 November 2023
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 25 (3-4) , 336-344
Autophagy dysregulation plays a crucial role in regulatory T-cell loss and neuroinflammation in amyotrophic lateral sclerosis (ALS)
Objective: Neuroinflammation is the hallmark of amyotrophic lateral sclerosis (ALS) disease. Regulatory T cells (Tregs) are essential in immune tolerance and neuroinflammation prevention. It has been shown that a significant decrease in Treg and FoxP3 protein expression is observed in ALS patients. The main reason for the FoxP3(+) Treg loss in ALS is unknown. In this study, the role of autophagy dysregulation in FoxP3(+) Tregs in ALS was investigated.Methods: Twenty-three ALS patients and 24 healthy controls were recruited for the study. Mononuclear cells (MNCs) were obtained from peripheral blood, and then Tregs were isolated. Isolated Tregs were stained with FoxP3 and LC3 antibodies and analyzed in flow cytometry to determine autophagy levels in FoxP3(+) Tregs in patients and controls.Results: The mean of FoxP3(+) LC3(+) cells, were 0.47 and 0.45 in patients and controls, respectively. The mean of FoxP3(+) LC3- cells was 0.15 in patients and 0.20 in controls, p = 0.030 (p < 0.05). There is no significant correlation between ALSFRS-R decay rate and autophagy level in patients. Also, there is no significant difference between autophagy levels in FoxP3(+) Tregs in patients with rapidly progressing ALS and slow-progressing ALS.Conclusion: Excessive autophagy levels in FoxP3(+) Tregs in ALS patients can potentially be an explanation for an increased cell death and result in worsened neuroinflammation and disease onset. However, the disease progress is not attributable to autophagy levels in FoxP3(+) Tregs.
- Open Access
- 27 January 2020
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 14 (1) , 72-79
Santral Tiroid Hormon Direnci Saptanan Olgularda Tiroid Hormon Reseptör Gen Analizi ve Periferik Direnç Eşliğinin Araştırılması.
Amaç: Hipofizer tiroid hormon (TH) direnci düşünülen ve klinik bulguların ayırdettirici olmadığı çocuk olgularda periferik direnç eşliğinin değerlendirilmesi ve TH β reseptörü (TRβ) mutasyon sıklığının belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Hipofizer TH direnci tanısı ile izlenen ve yeterli dozda levotiroksin (L-T4) tedavisi almalarına rağmen izlem süreçlerinde tiroid stimülan hormon (TSH) düzeyleri baskılanamayan, 20 olgu (13 kız, ort yaş 7.03±2.72 yıl,) çalışmaya alınmıştır. TH periferik etkileri, suprafizyolojik doz levotriiodotironin (L-T3) uygulaması öncesi ve sonrası serbest T3 (sT3), serbest T4 (sT4), TSH, seks hormon bağlayıcı globulin (SHBG), total kolesterol, alkalen fosfataz (ALP), osteokalsin, anjiotensin konverting enzim (ACE) düzeyleri ve kreatin fosfokinaz (CPK), M-mod ve Doppler ekokardiyografi (EKO) tetkikleri ile değerlendirilmiş ve TRβ gen analizleri yapılmıştır. Bulgular: Olguların L-T3 öncesi ve sonrası biyokimyasal ölçütleri karşılaştırıldığında SHBG, osteokalsin, ACE düzeylerinde anlamlı artış, total kolesterol ve CPK düzeylerinde ise anlamlı ölçüde azalma olduğu gözlenmiştir (pA değişimi saptanmıştır. Sonuç: Olgularımızda suprafizyolojik L-T3 konsantrasyonlarına değişik derecelerde periferik doku yanıtının gözlenmesi, yüksek T3 düzeylerine yanıtın korunduğunun göstergesidir ve en yüksek yanıtın oluştuğu SHBG ve CPK değişimleri yol gösterici olabilir. TRβ gen analizinde saptanan iki değişimin direnç patogenezinde rolü olmadığı düşünülmüştür. Yeterli tedavi kriterleri taşımalarına rağmen TSH düzeyleri ısrarlı yüksek seyreden doğumsal hipotiroid olgularda genetik bir anomali eşliğinden çok, hipotalamus-hipofiz-tiroid ekseninin intrauterin dönem olgunlaşma sürecindeki fonksiyonel bir hatanın sorumlu olduğu düşünülebilir.
- 27 January 2020
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 14 (1) , 72-79
Open AccessSantral Tiroid Hormon Direnci Saptanan Olgularda Tiroid Hormon Reseptör Gen Analizi ve Periferik Direnç Eşliğinin Araştırılması.
Amaç: Hipofizer tiroid hormon (TH) direnci düşünülen ve klinik bulguların ayırdettirici olmadığı çocuk olgularda periferik direnç eşliğinin değerlendirilmesi ve TH β reseptörü (TRβ) mutasyon sıklığının belirlenmesi amaçlanmıştır. Gereç ve Yöntemler: Hipofizer TH direnci tanısı ile izlenen ve yeterli dozda levotiroksin (L-T4) tedavisi almalarına rağmen izlem süreçlerinde tiroid stimülan hormon (TSH) düzeyleri baskılanamayan, 20 olgu (13 kız, ort yaş 7.03±2.72 yıl,) çalışmaya alınmıştır. TH periferik etkileri, suprafizyolojik doz levotriiodotironin (L-T3) uygulaması öncesi ve sonrası serbest T3 (sT3), serbest T4 (sT4), TSH, seks hormon bağlayıcı globulin (SHBG), total kolesterol, alkalen fosfataz (ALP), osteokalsin, anjiotensin konverting enzim (ACE) düzeyleri ve kreatin fosfokinaz (CPK), M-mod ve Doppler ekokardiyografi (EKO) tetkikleri ile değerlendirilmiş ve TRβ gen analizleri yapılmıştır. Bulgular: Olguların L-T3 öncesi ve sonrası biyokimyasal ölçütleri karşılaştırıldığında SHBG, osteokalsin, ACE düzeylerinde anlamlı artış, total kolesterol ve CPK düzeylerinde ise anlamlı ölçüde azalma olduğu gözlenmiştir (pA değişimi saptanmıştır. Sonuç: Olgularımızda suprafizyolojik L-T3 konsantrasyonlarına değişik derecelerde periferik doku yanıtının gözlenmesi, yüksek T3 düzeylerine yanıtın korunduğunun göstergesidir ve en yüksek yanıtın oluştuğu SHBG ve CPK değişimleri yol gösterici olabilir. TRβ gen analizinde saptanan iki değişimin direnç patogenezinde rolü olmadığı düşünülmüştür. Yeterli tedavi kriterleri taşımalarına rağmen TSH düzeyleri ısrarlı yüksek seyreden doğumsal hipotiroid olgularda genetik bir anomali eşliğinden çok, hipotalamus-hipofiz-tiroid ekseninin intrauterin dönem olgunlaşma sürecindeki fonksiyonel bir hatanın sorumlu olduğu düşünülebilir.
- 6 November 2012
- Published by Springer Nature in Rheumatology International
- Vol. 33 (11) , 2921-2925
Absence of the SLC22A12 gene mutation in Turkish population with primary gout disease
- 6 November 2012
- Published by Springer Nature in Rheumatology International
- Vol. 33 (11) , 2921-2925
Absence of the SLC22A12 gene mutation in Turkish population with primary gout disease
- Open Access
- 1 January 2011
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 14 (1) , 25-30
RLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients
RLIP76Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients: Approximately 30% of epileptic patients remain untreated, in spite of trials with maximum tolerable doses of more than one drug. The RalA binding protein 1 (RALBP1/RLIP76), a multifunctional, anti-apoptotic, multidrug transporter protein, has been proposed as being responsible for the drug resistance mechanism in epilepsy. We have investigated polymorphic differences in the coding regions and exon-intron boundaries of theRLIP76gene, between 146 refractory and 155 non refractory epileptic patients in Turkey, using denaturing high performance liquid chromatography (HPLC) and sequencing analysis techniques. We have detected the following sequence variants: c.160-4G>A, c.187C>G, c.1562-38G>A, c.1670+107G>A, c.1670+93G>A, c.1670+96G>A, c.1670+100C>T, c.1670+130C>T, c.1670+131G>C, c.1670+140 G>C, and found no statistically significant correlation between allele frequencies and drug response status. We conclude that sequence variants of this gene are not involved in drug resistance in epilepsy.
- 1 January 2011
- Published by Walter de Gruyter GmbH in Balkan Journal of Medical Genetics
- Vol. 14 (1) , 25-30
Open AccessRLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients
RLIP76Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients: Approximately 30% of epileptic patients remain untreated, in spite of trials with maximum tolerable doses of more than one drug. The RalA binding protein 1 (RALBP1/RLIP76), a multifunctional, anti-apoptotic, multidrug transporter protein, has been proposed as being responsible for the drug resistance mechanism in epilepsy. We have investigated polymorphic differences in the coding regions and exon-intron boundaries of theRLIP76gene, between 146 refractory and 155 non refractory epileptic patients in Turkey, using denaturing high performance liquid chromatography (HPLC) and sequencing analysis techniques. We have detected the following sequence variants: c.160-4G>A, c.187C>G, c.1562-38G>A, c.1670+107G>A, c.1670+93G>A, c.1670+96G>A, c.1670+100C>T, c.1670+130C>T, c.1670+131G>C, c.1670+140 G>C, and found no statistically significant correlation between allele frequencies and drug response status. We conclude that sequence variants of this gene are not involved in drug resistance in epilepsy.
- 1 December 2010
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 203 (2) , 230-237
Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients
- 1 December 2010
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 203 (2) , 230-237
Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients
- 1 January 2005
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 22 (4) , 291-295
COMBINATION OF IVS2.849 A-G WITH IVS1.1 G-A: A Mutation of ?-Globin Gene in a Turkish ?-Thalessemia Major Patient
Beta-thalassemia, which is an autosomal recessive disease, is among the most common hemoglobinopathies in Antalya, Turkey. Mutations found in Turkish beta-thalassemia patients constitute a heterogeneous group, which is mostly composed of point mutations and, only in very rare cases, a deletion or an insertion causes affected or carrier phenotypes. Reverse dot blot hybridization (RDBH) method is used for screening common mutations, and sequence analysis and silver staining were performed consecutively to detect any uncommon mutation. The authors report a first Turkish family with a rare variant--intervening sequence 2 (IVS2) 849 (A-G). The proband's mother and father were determined as carriers of IVS2.849 (A-G) and IVS1.1 (G-A) mutations, respectively. Proband is the first child of the family and she has an IVS2.849 (A-G)/IVS1.1 (G-A) genotype with ss-thalassemia major phenotype. Prenatal diagnosis was performed for the second child, and genotype of the fetus was determined as IVS2.849 (A-G)/Normal. This first report of IVS2.849 (A-G) mutation in Turkish population shows that there are many more mutations contributing the heterogeneity of the mutation spectrum of beta-globin gene in the Turkish population, which indicates migrations of different ethnic origins.
- 1 January 2005
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 22 (4) , 291-295
COMBINATION OF IVS2.849 A-G WITH IVS1.1 G-A: A Mutation of ?-Globin Gene in a Turkish ?-Thalessemia Major Patient
Beta-thalassemia, which is an autosomal recessive disease, is among the most common hemoglobinopathies in Antalya, Turkey. Mutations found in Turkish beta-thalassemia patients constitute a heterogeneous group, which is mostly composed of point mutations and, only in very rare cases, a deletion or an insertion causes affected or carrier phenotypes. Reverse dot blot hybridization (RDBH) method is used for screening common mutations, and sequence analysis and silver staining were performed consecutively to detect any uncommon mutation. The authors report a first Turkish family with a rare variant--intervening sequence 2 (IVS2) 849 (A-G). The proband's mother and father were determined as carriers of IVS2.849 (A-G) and IVS1.1 (G-A) mutations, respectively. Proband is the first child of the family and she has an IVS2.849 (A-G)/IVS1.1 (G-A) genotype with ss-thalassemia major phenotype. Prenatal diagnosis was performed for the second child, and genotype of the fetus was determined as IVS2.849 (A-G)/Normal. This first report of IVS2.849 (A-G) mutation in Turkish population shows that there are many more mutations contributing the heterogeneity of the mutation spectrum of beta-globin gene in the Turkish population, which indicates migrations of different ethnic origins.
- 28 August 2004
- Vol. 24 (4) , 2547-9
Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer.
The RNASEL G1385A variant was recently found to be implicated in the development of prostate cancer. Considering the function of RNase L and the pleiotropic effects of mutations associated with cancer, we sought to investigate whether the RNASEL G1385A variant is a risk factor for breast cancer. A total of 453 breast cancer patients and 382 age- and sex-matched controls from Greece and Turkey were analyzed. Genotyping for the RNASEL G1385A variant was performed using an Amplification Refractory Mutation System (ARMS). Statistical evaluation of the RNASEL G1385A genotype distribution among breast cancer patients and controls revealed no significant association between the presence of the risk genotype and the occurrence of breast cancer. Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk; this variant does not appear to be implicated in the development of breast cancer.
- 28 August 2004
- Vol. 24 (4) , 2547-9
Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer.
The RNASEL G1385A variant was recently found to be implicated in the development of prostate cancer. Considering the function of RNase L and the pleiotropic effects of mutations associated with cancer, we sought to investigate whether the RNASEL G1385A variant is a risk factor for breast cancer. A total of 453 breast cancer patients and 382 age- and sex-matched controls from Greece and Turkey were analyzed. Genotyping for the RNASEL G1385A variant was performed using an Amplification Refractory Mutation System (ARMS). Statistical evaluation of the RNASEL G1385A genotype distribution among breast cancer patients and controls revealed no significant association between the presence of the risk genotype and the occurrence of breast cancer. Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk; this variant does not appear to be implicated in the development of breast cancer.